Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Our Editorial Board

Editor's pick

11-01-2019 | Tyrosine kinase inhibitors | News

Concomitant TKI–PPI use may adversely affect cancer patient survival

Taking proton pump inhibitors alongside tyrosine kinase inhibitors is associated with an increased mortality risk in older cancer patients, research indicates.

08-01-2019 | Cutaneous T-cell lymphoma | Brief review | Article

Emerging therapies for cutaneous T-cell lymphoma

Cutaneous T-cell lymphomas are a heterogeneous group of T-lymphocyte malignancies with only one potentially curative treatment option that has limited applicability. Dawn Queen, Adriana Lopez, and Larisa Geskin (Columbia University Medical Center, USA) explore the most promising emerging alternative treatment options. 

12-12-2018 | Immunotherapy | Feature | Article

Hyperprogression as a response to immunotherapy: ‘A serious downside’

In light of recent reports of hyperprogression in response to treatment with cancer immunotherapy, medwireNews spoke to medical oncologist Razelle Kurzrock (University of California, San Diego, La Jolla, USA) about the phenomenon, the implications for therapy, and future directions for research.

Specialty

Latest from across the site

16-01-2019 | Castration-resistant prostate cancer | News

Germline BRCA2 mutations impact mCRPC survival

Germline mutations in the BRCA2 gene, but not other DNA damage repair genes, are associated with poorer outcomes among patients with metastatic castration-resistant prostate cancer, study findings indicate.

Source:

J Clin Oncol 2019; doi:10.1200/JCO.18.00358

15-01-2019 | Non-small cell lung cancer | News

miRNA signature could supplement PD-L1 as NSCLC immunotherapy marker

Combining a plasma-based microRNA signature with tumoral tissue expression of programmed cell death ligand 1 could help identify advanced non-small-cell lung cancer patients who are unlikely to benefit from immune checkpoint inhibition, suggests an exploratory study.

Source:

Clin Cancer Res 2019; doi:10.1158/1078-0432.CCR-18-1981

14-01-2019 | Bladder cancer | News

Smoking associated with unfavorable neoadjuvant therapy response in bladder cancer

Patients with muscle-invasive bladder cancer who are current or former smokers are more likely to respond poorly to cisplatin-based neoadjuvant chemotherapy than their nonsmoking counterparts, researchers report in BJU International.

Source:

BJU Int 2019; doi:10.1111/bju.14612

11-01-2019 | Chemoprevention | News

News in brief

COMT gene modifies chemopreventive effects of vitamin E

Vitamin E supplementation may reduce the risk for cancer but only in individuals harboring a particular allele of the catechol-O-methyltransferase gene, suggests an analysis of two randomized trials.

11-01-2019 | Tyrosine kinase inhibitors | News

Concomitant TKI–PPI use may adversely affect cancer patient survival

Taking proton pump inhibitors alongside tyrosine kinase inhibitors is associated with an increased mortality risk in older cancer patients, research indicates.

Source:

Cancer 2019; doi:10.1002/cncr.31917

10-01-2019 | Non-small cell lung cancer | News

Autoimmune antibodies predict clinical benefit, adverse events in NSCLC

The presence of some autoimmune antibodies prior to treatment with programmed cell death protein 1 inhibitors is associated with both clinical benefit and immune-related adverse events in patients with non-small-cell lung cancer, researchers report.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.5860

Steering improved outcomes in non-driver mutation lung cancer: Progress and challenges

Steering improved outcomes in lung cancer

This program was made possible thanks to an independent educational grant from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Gastric cancer care: From evidence to practice

Gastric cancer care

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Scientific summary

Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

This program was made possible thanks to independent educational sponsorship from MorphoSys.

Soft tissue sarcoma: What is best practice?

 Soft tissue sarcoma: What is best practice?

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Latest from us on Twitter

Updates from oncology organizations

New Content Item Meet our Advisory Board

image credits